文 献 8）Ribbing J, Niclas JE. Power, selection bias and predictive performance of the population p h a r m a c o k i n e t i c c o v a r i a t e m o d e l . J Pharmacokinet Pharmacodyn 2004; 31: 109-34. 9）Minto CF, Schnider TW, Egan TD, Youngs E, Lemmens HJM, Gambus PL, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil: I. Model development. Anesthesiology 1997; 86(1): 10-23.10）Traynard P, Ayral G, Twarogowska M, Chauvin J. Efficient pharmacokinetic modeling workflow with the MonolixSuite: a case study of remifentanil．CPT Pharmacometrics Syst Pharmacol 2020; 9(4): 198-210.11）Miljkovic F, Martinsson A, Obrezanova O, Williamson B, Johnson M, Sykes A, et al. Machine learning models for human in vivo pharmacokinetic parameters with in-house validation. Mol Pharm 2021; 18(12): 4520-30.12）Handa K, Wright P, Yoshimura S, Kageyama M, Iijima T, Bender A. Prediction of compound plasma concentration-time profiles in mice using random forest. Mol Pharm 2023; 20(6): 3060-72.13）Ette EI, Williams PJ. Population pharmacokinetics II: estimation methods. Ann Pharmacother 2004; 38(11): 1907-15.14）Iwata H, Kageyama M, Handa K. Machine learning prediction and validation of plasma concentration time profiles. Mol Pharm 2025; 22(6): 2976-84.86 1）Schlander M, Hernandez-Villafuerte K, Cheng CY, Mestre-Ferrandiz J, Baumann M. How much does it cost to research and develop a new drug? A systematic review and assessment. Pharmacoeconomics 2021; 39(11): 1243-69. 2）Marshall S, Madabushi R, Manolis E, Krudys K, Staab A, Dykstra K, et al. Model-informed drug discovery and development: current industry good practice and regulatory expectations and future perspectives. CPT Pharmacometrics Syst Pharmacol 2019; 8(2): 87-96． 3）Ota R, Yamashita F. Application of machine learning techniques to the analysis and prediction of drug pharmacokinetics. J Control Release 2022; 352: 961-9． 4）Janssen A, Bennis FC, Mathot RAA. Adoption of machine learning in pharmacometrics: an overview of recent implementations and their considerations. pharmaceutics 2022; 14(9): 1814. 5）Bram DS, Nahum U, Atkinson A, Koch G, Pfister M. Evaluation of machine learning methods for covariate data imputation in pharmacometrics. CPT Pharmacometrics Syst Pharmacol 2022; 11(12): 1638-48. 6）Sibieude E, Khandelwal A, Hesthaven JS, Girard P, Terranova N. Fast screening of covariates in population models empowered by machine learning. J Pharmacokinet Pharmacodyn 2021; 48(4): 597-609. 7）Del Valle-Moreno P, Suarez-Casillas P, M e j i a s - T r u e b a M , C i u d a d - G u t i e r r e z P , Guisado-Gil AB, Gil-Navarro MV, et al. Model-informed precision dosing software tools for dosage regimen individualization: a scoping review. Pharmaceutics 2023; 15(7): 1859.
元のページ ../index.html#102